Not yet recruitingNCT07877623MINCUpdated Oct 16, 2026

CLINICAL INTUITION is an Experience-based, Often Unconscious Assessment of a Patient's Resilience and Tolerance. It is INFLUENCED by Clinical Signs, Behavior, Functioning, and Context. While it MAY PREDICT Patient Dropout, it is Difficult to Objectify.

An observational study in Clinical Intuition, sponsored by Erasmus Medical Center. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Erasmus Medical Center · Observational

Updated Oct 16, 2026Newly registeredGo to Updates ↓

Study type: Observational
Model: Other
Time perspective: Other
Enrollment: 10
Sex: All

Study summary

Patient selection for Phase I oncology trials is formally based on protocol-defined inclusion and exclusion criteria. In practice, however, healthcare professionals also take clinical intuition and professional experience into account when assessing suitability. The role of this intuitive judgment is insufficiently described in the literature, even though it may be relevant for preventing early trial discontinuation.

Conditions studied

Clinical Intuition

Keywords

Clinical Intuition

In context

Lead sponsor

Erasmus Medical Center is the lead sponsor of 478 studies on the registry; 183 are open to participants now.

Browse Erasmus Medical Center studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: Yes
Sampling method: Non-probability sample

Study population

Oncologists and nurse specialists involved in patient selection for Phase I trials at Erasmus MC.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthcare professionals working within or closely affiliated with the Erasmus MC Phase I team.
Direct involvement in eligibility assessment and recruitment for Phase I oncology studies.
Ability to communicate in Dutch.
Provision of written informed consent.

Exclusion criteria

Exclusion Criteria:

No involvement in patient selection in phase I.
Inability or unwillingness to provide consent.
Insufficient availability to participate in an interview.

Study design

Observational model: Other
Time perspective: Other
Enrollment: 10 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

Role and value of clinical intuition
The aim of this study is to explore how healthcare professionals perceive the role and value of clinical intuition when assessing patient suitability for phase I oncology trials.
Time frame: During the single-session interview (approximately 45-60 minutes)

Secondary outcomes

Definition
Investigating how healthcare professionals define clinical intuition
Time frame: During the single-session interview (approximately 45-60 minutes)
Identify
Identify clinical, functional, and psychosocial factors contributing to intuitive judgment.
Time frame: During the single-session interview (approximately 45-60 minutes)

Study locations

No study locations are listed for this record.

Timeline

1 registry update since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered: Oct 9, 2026
First posted: Oct 16, 2026
StartEst.: Oct 29, 2026
Primary completionEst.: Jan 2027
CompletionEst.: May 2027
Last update: Oct 16, 2026

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

Registered

First appeared on the registry. No changes since

Oct 16, 2026

Show all 1 update

Oct 16, 2026
First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07877623
Lead sponsor: Erasmus Medical Center
Responsible party: Stephan Lugten (Nurse Practitioner in training, Erasmus Medical Center) — Principal investigator
First posted: Oct 16, 2026
Start date: Oct 29, 2026 (estimated)
Primary completion: Jan 2027 (estimated)
Completion: May 2027 (estimated)
Last update: Oct 16, 2026

Study contacts

Stephan Lugten

Contact

s.lugten@erasmusmc.nl

+31652905479

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Erasmus Medical Center →

Start the discussion